A novel variant of the CASQ2 gene in a Chinese family with catecholaminergic polymorphic ventricular tachycardia by Gao, Lu et al.
Address for correspondence: Dr. Yue Yuan, Beijing Children’s Hospital, Capital Medical University, National Center for  
Children’s Health, China, 100045, Postal code: 100045, China, tel: +8613366971016, e-mail: yuanyuebj22@163.com
Received: 8.08.2018 Accepted: 2.09.2018
*Lu Gao and Lang Cui are both the first author.
CLINICAL CARDIOLOGY
Cardiology Journal 
2018, Vol. 25, No. 6, 756–758
DOI: 10.5603/CJ.2018.0155 
Copyright © 2018 Via Medica
ISSN 1897–5593
756 www.cardiologyjournal.org
LETTER TO THE EDITOR
A novel variant of the CASQ2 gene  
in a Chinese family with catecholaminergic  
polymorphic ventricular tachycardia
Lu Gao1*, Lang Cui1*, Lihui Zheng2, Zhihui Zhao1, Qirui Li1,  
Xia Yu1, Jiahui Wang3, Yue Yuan1
1Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, China 
2Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China 
3Sinopath Diagnostics, Beijing, China
Catecholaminergic polymorphic ventricular 
tachycardia (CPVT) is an inherited cardiac disorder 
which is potentially lethal and is characterized by 
episodic bidirectional or polymorphic ventricular 
tachycardia during adrenergic stimulation, without 
apparent structural heart disease. The prevalence 
of this rare fatal disease has been estimated to 
be approximately 1:10000 [1]. However, early 
diagnosis of CPVT is difficult due to a patients’ 
normal heart structure and generally normal rest-
ing electrocardiogram. Gene testing is particularly 
important in diagnosis, and early diagnosis and 
treatment can effectively prevent sudden death in 
children [2].
Regulation of calcium flux in the heart is a key 
process that affects cardiac excitability and con-
tractility. Mutations in  gene encoding ryanodine 
receptor 2 (RYR2) and calsequestrin 2 (CASQ2) 
are the most common causes of cardiomyocyte 
calcium imbalance [3].  This study documents the 
case of a Chinese family with CPVT. Clinical and 
exercise stress testing results of the patients were 
analyzed in detail, and targeted exome sequencing 
technology was applied. 
The diagnosis of CPVT can be based on: 1) In the 
presence of a structurally normal heart and coronary 
arteries, normal electrocardiogram, unexplained 
exercise or catecholamine-induced bidirectional ven-
tricular tachycardia (BVT), polymorphic premature 
ventricular contractions (PVCs) or ventricular tachy-
cardia in individuals < 40 years old; 2) A pathogenic 
mutation; 3) Family members of a CPVT index case 
with a normal heart who manifests exercise-induced 
PVCs or BVT/PVT [4]. This Chinese family has 
5 children, 3 daughters and 2 sons. The proband is 
the second daughter and her two younger brothers, 
who all met the diagnostic criteria for CPVT. 
Many previous studies have confirmed syn-
cope as the main clinical symptom of CPVT [5, 6]. 
The 12-year-old proband experienced recurrent 
syncope 5–6 times per year since the age of 5, and 
was diagnozed with epilepsy. She  failed to respond 
to oral antiepileptic medication for seizures. When 
she was 12 years old, ventricular tachycardia was 
demonstrated in a routine 24 h Holter examination. 
During exercise stress testing, polymorphic ven-
tricular arrhythmia was induced at a heart rate of 
126 bpm in stage III. One of the proband brothers, 
the fourth child in this family, was 10 years old and 
experienced syncope during exercise at 8 years 
old. During exercise stress testing, polymorphic 
ventricular arrhythmia was induced at a heart rate 
of 125 bpm in stage IV. The other younger brother 
of the proband is 5 years old, and had experienced 
syncope 3 days prior to exercise. Exercise stress 
testing was also performed; when the heart rate 
reached 125 bpm in stage IV, ventricular prema-
ture beats began to appear. No abnormality in the 
proband or her 2 younger brothers was detected 
on physical examination, echocardiography, elec-
trocardiography or regarding cerebral blood flow. 
In each case, the impact of drugs and electrolyte 
disorder could be excluded. Exercise stress tests 
of the proband’s parents and sisters were negative. 
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Figure 1. A. Sequencing results and bioinformatic analysis of the gene mutation in this study; B. Polyphen-2 score 
of the novel damaging mutation c.748C>T (p.R250C); C. SIFT score of the novel damaging mutation c.748C>T 
(p.R250C); D. The mutation site is conserved across multiple species; E. PSIPRED prediction of the polypeptide chain 
secondary structure.
To further confirm the diagnoses, Next Gen-
eration Sequencing technology was applied for 
the proband. The QIAamp DNA Mini Kit (Qiagen, 
Germany) was used to isolate genomic DNA from 
peripheral blood leukocytes. Comprehensive de-
tection of genetic cardiovascular diseases was 
performed using the SeqCap EZ Choice XL Library 
(Roche NimbleGen). Next, exome sequencing data 
were generated by 150 bp end reads on the Illumina 
Hiseq 4000 and analyzed in house pipeline. Paired-
end reads in the FASTQ files were mapped on to 
the human reference genome sequence (GRCh37/
hg19), revealing two heterozygous mutations 
c.97C>T(p.R33X) and c.748C>T(p.R250C) in the 
CASQ2 gene. Blood samples were collected from 
the proband’s family for gene sequencing.
Sanger sequencing confirmed that mutation 
c.97C>T(p.R33X) in the CASQ2 gene was in-
herited from the proband’s father. This nonsense 
mutation leads to early termination of protein poly-
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peptide synthesis and is a known mutation reported 
by the Human Gene Mutation Database [7].
This article will focus primarily on the 
c.748C>T mutation (Fig. 1A), in which the argi-
nine at codon 250 (p.R250C) was substituted by 
cysteine. This mutation was found in the proband’s 
mother and had not been previously reported; 
the proband and her 2 younger brothers were 
all heterozygous carriers. The variant c.748C>T 
(p.R250C) was not observed in approximately 
10,000 samples in the Sinopath laboratory data-
base (undisclosed) from individuals of Chinese 
backgrounds and some databases like ExAC/ESP, 
indicating that it is not a common benign variant 
or a polymorphism in these populations. Silico al-
gorithms PolyPhen-2, SIFT and Mutation_Taster 
all predicted it to be deleterious. In addition, it was 
predicted to cause possible damage by Polyphen-2 
with a score of 0.973 (Fig. 1B), and SIFT predicted 
this mutation to be damaging, with a score of 0.05 
(Fig. 1C). According to the University of California 
Santa Cruz (UCSC) database, this mutation site is 
conserved across multiple species (Fig. 1D). Use 
of PSIPRED to predict the secondary structure of 
the polypeptide chain determined that there was 
a novel alpha helix at the original 260 amino acid po-
sition. However, the mutation in the gene resulted 
in the disappearance of the alpha helix in the cor-
responding protein polypeptide chain, most likely 
further affecting its corresponding protein space 
structure or related protein function (Fig. 1E).
The structure and function of proteins is de-
termined by some key amino acids. When these 
amino acids are changed, the proteins also change. 
If the site of a mutation is in a very conservative 
position, then the variation may have a greater 
impact on the structure and function. The site of 
the p.R250C mutation in the UCSC database query 
shows that it is conserved across many species, 
so it is highly likely that the changes may have an 
impact on protein function.
Pharmacological therapy was prescribed to 
of the 3 subjects. The proband and her 2 younger 
brothers were all given oral beta-blocker metopro-
lol at 2 mg/kg. After pharmacological therapy, the 
patients did not faint again.
In this study, a pedigree of catecholamine-
sensitive pleomorphic ventricular tachycardia 
based was diagnosed from clinical manifestations, 
exercise stress testing and genetic analysis. 
A new heterozygous mutation site c.748C>T in the 
CASQ2 gene was detected, which resulted in the 
substitution of arginine at codon 250 by cysteine. 
These results extend the genetic mutation spec-
trum of CASQ2 and demonstrate that targeted 
exome sequencing is an effective method for the 
diagnosis of CPVT in clinical practices.
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